Cholesterol and glycemic effects of Niaspan in patients with type 2 diabetes.
| Title: | Cholesterol and glycemic effects of Niaspan in patients with type 2 diabetes. |
|---|---|
| Authors: | Kane MP; Department of Pharmacy Practice, Albany College of Pharmacy, New York 12208, USA. kanem@acp.edu; Hamilton RA; Addesse E; Busch RS; Bakst G |
| Source: | Pharmacotherapy [Pharmacotherapy] 2001 Dec; Vol. 21 (12), pp. 1473-8. |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Language: | English |
| Journal Info: | Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 8111305 Publication Model: Print Cited Medium: Print ISSN: 0277-0008 (Print) Linking ISSN: 02770008 NLM ISO Abbreviation: Pharmacotherapy Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2012- : Malden, MA : Wiley-Blackwell; Original Publication: [Carlisle, MA : Pharmacotherapy Publications, c1981- |
| MeSH Terms: | Blood Glucose/*analysis ; Cholesterol/*blood ; Diabetes Mellitus, Type 2/*drug therapy ; Hypolipidemic Agents/*therapeutic use ; Niacin/*therapeutic use; Diabetes Mellitus, Type 2/blood ; Female ; Humans ; Male ; Middle Aged ; Retrospective Studies |
| Abstract: | Study Objective: To determine the effect of Niaspan--a niacin preparation with both immediate- and extended-release characteristics--on lipid and glycemic control in patients with type 2 diabetes.; Design: Retrospective study; Setting: Private-practice endocrinology group.; Patients: Thirty-two patients (mean age 60 yrs; 72% men) with type 2 diabetes identified by a computerized text search.; Intervention: Patients received Niaspan 1000, 1500, or 2000 mg/day (median daily dosage 1000 mg).; Measurements and Main Results: Total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, triglycerides, hemoglobin A1c, and transaminase levels were compared for each patient before and 6 months after initiation of Niaspan. Niaspan therapy was associated with a significant 34% increase in HDL (p=0.033), a significant 36% reduction of triglycerides (p=0.049), and no significant change in LDL (p=0.236) or total cholesterol (p=0.122). Mean hemoglobin A1c levels significantly decreased from baseline by 0.5 +/- 0.3% (p=0.032), even though dosages and treatment with antidiabetic agents remained constant. There were no significant changes in transaminase levels. Seven patients (21.9%) discontinued Niaspan; one of them experienced an increase in blood glucose while receiving the agent.; Conclusion: For most patients with type 2 diabetes, Niaspan is a safe and effective therapy for dyslipidemia and does not exacerbate glycemic control. |
| Substance Nomenclature: | 0 (Blood Glucose); 0 (Hypolipidemic Agents); 2679MF687A (Niacin); 97C5T2UQ7J (Cholesterol) |
| Entry Date(s): | Date Created: 20020105 Date Completed: 20020508 Latest Revision: 20190916 |
| Update Code: | 20260130 |
| DOI: | 10.1592/phco.21.20.1473.34481 |
| PMID: | 11765300 |
| Database: | MEDLINE |
Journal Article; Research Support, Non-U.S. Gov't